A microfluidic application for mass production of drug-loaded polymeric microspheres for a long-acting injectable with IVL-DrugFluidic®, a novel microfluidic microsphere manufacturing platform technology
July 2023
in “OpenNano”
We don't know much about this study yet.
We're trying to become the world's largest resposity of hair loss research. You can help out the community by sending a PDF of this study here . Not sure how to get a study's PDF? You can email the authors of the study.Cited in this study
research Three months extended-release microspheres prepared by multi-microchannel microfluidics in beagle dog models
A new device, IVL-PPF Microsphere®, was created to deliver a hair loss drug for up to 3 months with one injection, potentially replacing daily pills.
research Pharmacokinetic-pharmacodynamic modeling approach for dose prediction of the optimal long-acting injectable formulation of finasteride
Optimal long-acting finasteride injection dose found: 16.8 mg, effective for one month.
research 5‐Alpha reductase inhibitors in androgenetic alopecia: Shifting paradigms, current concepts, comparative efficacy, and safety
Dutasteride works better than finasteride for hair loss, with both being safe to use.
research Assessment of the usefulness of dihydrotestosterone in the diagnostics of patients with androgenetic alopecia
DHT's role in hair loss is important, but measuring its level for diagnosis is questionable.
research Efficacy and Safety of Finasteride Therapy for Androgenetic Alopecia
Finasteride helps hair growth but may cause sexual side effects.
research Finasteride in the treatment of men with androgenetic alopecia
Finasteride safely and effectively treats male pattern hair loss, but may cause reversible sexual issues and harm male fetuses.